Published online 11 November 2017 | David S. Wishart1,2,3.*, Yannick Djoumbou Feunang1, Ana Marcu1, An Chi Guo1, Kevin Liang1, Rosa Vázquez-Fresno1, Tanvir Sajed2, Daniel Johnson1, Carin Li1, Naama Karu1, Zinat Sayeeda2, Elvis Lo1, Nazanin Assempour1, Mark Berjanskii1, Sandeep Singhal1, David Arndt1, Yongjie Liang1, Hasan Badran1, Jason Grant1, Arnau Serra-Cayuela1, Yifeng Liu2, Rupa Mandal1, Vanessa Neveu4, Allison Pon1,5, Craig Knox1,5, Michael Wilson1,5, Claudine Manach6 and Augustin Scalbert4
The Human Metabolome Database (HMDB) has been updated to version 4.0, representing the most significant upgrade in its history. This update includes a nearly threefold increase in the number of fully annotated metabolites, a nearly fourfold increase in experimental spectra, and a nearly 60-fold increase in illustrated metabolic pathways. New features include predicted MS/MS and GC-MS reference spectral data, predicted metabolite structures, and data on metabolite-SNP interactions and drug effects on metabolite levels. The database has also improved its chemical taxonomy, spectral viewing, and searching tools, enhancing its usability and applicability in various fields such as nutrition, biochemistry, clinical chemistry, and metabolomics.The Human Metabolome Database (HMDB) has been updated to version 4.0, representing the most significant upgrade in its history. This update includes a nearly threefold increase in the number of fully annotated metabolites, a nearly fourfold increase in experimental spectra, and a nearly 60-fold increase in illustrated metabolic pathways. New features include predicted MS/MS and GC-MS reference spectral data, predicted metabolite structures, and data on metabolite-SNP interactions and drug effects on metabolite levels. The database has also improved its chemical taxonomy, spectral viewing, and searching tools, enhancing its usability and applicability in various fields such as nutrition, biochemistry, clinical chemistry, and metabolomics.